Australian National University, Canberra, Australia.
PLoS One. 2010 Nov 24;5(11):e14103. doi: 10.1371/journal.pone.0014103.
The potential of the cardiac persistent sodium current as a target for protection of the myocardium from ischaemia and reperfusion injury is gaining increasing interest. We have investigated the anti-ischaemic and antiarrhythmic effects of riluzole, a selective INaP blocker, in an open chest pig model of infarction.
The left anterior descending coronary artery (LAD) was ligated in 27 anesthetised pigs (landrace or large white, either sex, 20-35 kg) which had received riluzole (8 mg/kg IP; n = 6), lidocaine (2.5-12 mg/kg bolus plus 0.05-0.24 mg/kg/min; n = 11) or vehicle (n = 10) 50 min prior. Arrhythmias could be delineated into phase 1a (0 to 20 min), phase 1b (20 to 50 min) and phase 2 (from 50 min to termination at 180 min) and were classified as premature ventricular contractions (PVCs), non-sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) (spontaneously reverting within 15 s) or sustained VT or VF (ie. requiring cardioversion at 15 s). Riluzole reduced the average number of all arrhythmias in Phase 2 (PVCs from 484+/-119 to 32+/-13; non sustained arrhythmias from 8.9+/-4.4 to 0.7+/-0.5; sustained arrhythmias from 3.9+/-2.2 to 0.5+/-0.4); lidocaine reduced the average number of non-sustained and sustained arrhythmias (to 0.4+/-0.3 and 0.4+/-0.3 respectively) but not PVCs (to 390+/-234). Riluzole and lidocaine reduced the average number of sustained arrhythmias in phase 1b (from 1.8+/-0.4 to 0.17+/-0.13 (p<0.02) and to 0.55+/-0.26 (p = ns) respectively). Neither lidocaine or riluzole changed the ECG intervals: there was no statistical significance between groups at time zero (just before ligation) for any ECG measure. During the course of the 3 hour period of the ischaemia R-R, and P-R intervals shortened slightly in control and riluzole groups (not significantly different from each other) but not in the lidocaine group (significantly different from control). QRS and QTc did not change appreciably in any group Riluzole reduced the degree of histopathological tissue damage across the infarct zone considerably more than did lidocaine.
At the doses used, riluzole was at least as effective as lidocaine at reducing the number of episodes of ischaemic VT or VF in pigs, and much more effective at reducing the number of PVCs. We propose that this is related to the ability of riluzole to block cardiac persistent sodium current.
心肌缺血再灌注损伤的心脏持续钠电流作为靶点的潜力越来越受到关注。我们研究了利鲁唑,一种选择性 INaP 阻断剂,在开胸猪模型中的抗缺血和抗心律失常作用。
在接受利鲁唑(8mg/kg IP;n=6)、利多卡因(2.5-12mg/kg 推注加 0.05-0.24mg/kg/min;n=11)或载体(n=10)预处理 50min 后,结扎 27 只麻醉猪(长白或大白,雌雄,20-35kg)的左前降支冠状动脉(LAD)。心律失常可分为 1a 期(0 至 20min)、1b 期(20 至 50min)和 2 期(从 50min 到 180min 结束),并分为室性早搏(PVCs)、非持续性室性心动过速(VT)或心室颤动(VF)(15s 内自行恢复)或持续性 VT 或 VF(即 15s 内需要电复律)。利鲁唑减少了 2 期所有心律失常的平均次数(PVC 从 484+/-119 降至 32+/-13;非持续性心律失常从 8.9+/-4.4 降至 0.7+/-0.5;持续性心律失常从 3.9+/-2.2 降至 0.5+/-0.4);利多卡因减少了非持续性和持续性心律失常的平均次数(分别降至 0.4+/-0.3 和 0.4+/-0.3),但不减少 PVC 次数(降至 390+/-234)。利鲁唑和利多卡因减少了 1b 期持续性心律失常的平均次数(分别降至 0.17+/-0.13(p<0.02)和 0.55+/-0.26(p=ns))。利多卡因或利鲁唑均未改变心电图间期:在结扎前(即时间为零),各组之间的任何心电图测量均无统计学意义。在缺血 3 小时期间,控制组和利鲁唑组的 R-R 和 P-R 间期略有缩短(彼此间无显著差异),但利多卡因组无明显缩短(与对照组有显著差异)。在任何一组中,QRS 和 QTc 均无明显变化。利鲁唑显著减少梗塞区的组织损伤程度,其效果明显优于利多卡因。
在使用的剂量下,利鲁唑在减少猪缺血性 VT 或 VF 的发作次数方面至少与利多卡因一样有效,而减少 PVC 的发作次数则更有效。我们认为这与利鲁唑阻断心肌持续钠电流的能力有关。